ImmunoGen, Inc. (NASDAQ:IMGN) – Research analysts at William Blair issued their FY2020 earnings per share (EPS) estimates for shares of ImmunoGen in a research note issued on Friday. William Blair analyst A. Hsieh forecasts that the biotechnology company will earn ($1.42) per share for the year.

ImmunoGen (NASDAQ:IMGN) last released its quarterly earnings data on Friday, November 3rd. The biotechnology company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.42). The business had revenue of $8.50 million during the quarter, compared to analyst estimates of $26.09 million. During the same period in the prior year, the business posted ($0.51) EPS. The business’s revenue for the quarter was up 10.4% on a year-over-year basis.

WARNING: “ImmunoGen, Inc. Expected to Post FY2020 Earnings of ($1.42) Per Share (IMGN)” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/immunogen-inc-expected-to-post-fy2020-earnings-of-1-42-per-share-imgn/1688987.html.

Several other equities research analysts have also recently weighed in on IMGN. Zacks Investment Research upgraded ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a report on Tuesday, October 31st. Canaccord Genuity set a $8.00 price objective on ImmunoGen and gave the stock a “buy” rating in a report on Monday, July 31st. Cantor Fitzgerald reiterated a “hold” rating and issued a $5.00 price objective on shares of ImmunoGen in a report on Friday, November 3rd. Jefferies Group LLC reiterated a “buy” rating and issued a $9.00 price objective on shares of ImmunoGen in a report on Monday, August 7th. Finally, ValuEngine lowered ImmunoGen from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $7.83.

ImmunoGen (NASDAQ IMGN) traded up $0.05 during midday trading on Monday, reaching $5.59. The company’s stock had a trading volume of 1,713,456 shares, compared to its average volume of 3,744,617. ImmunoGen has a 1-year low of $1.53 and a 1-year high of $8.84. The company has a debt-to-equity ratio of -0.56, a current ratio of 2.40 and a quick ratio of 2.34.

In other news, VP Craig Barrows sold 37,050 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $6.81, for a total value of $252,310.50. Following the completion of the transaction, the vice president now owns 51,100 shares of the company’s stock, valued at approximately $347,991. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.51% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. FMR LLC increased its position in ImmunoGen by 598.9% during the 2nd quarter. FMR LLC now owns 5,605,285 shares of the biotechnology company’s stock valued at $39,854,000 after buying an additional 4,803,256 shares in the last quarter. State Street Corp increased its position in ImmunoGen by 159.1% during the 2nd quarter. State Street Corp now owns 4,141,583 shares of the biotechnology company’s stock valued at $29,450,000 after buying an additional 2,542,876 shares in the last quarter. Redmile Group LLC increased its position in ImmunoGen by 30.8% during the 2nd quarter. Redmile Group LLC now owns 5,212,736 shares of the biotechnology company’s stock valued at $37,063,000 after buying an additional 1,228,002 shares in the last quarter. EAM Investors LLC bought a new position in ImmunoGen during the 2nd quarter valued at approximately $4,144,000. Finally, Candriam Luxembourg S.C.A. bought a new position in ImmunoGen during the 2nd quarter valued at approximately $4,053,000. 72.99% of the stock is owned by hedge funds and other institutional investors.

About ImmunoGen

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Earnings History and Estimates for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.